Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes. (January 2017)

• Record Type: Journal Article
• Authors: Flahault, Adrien; Anglicheau, Dany; Loriot, Marie-Anne; Thervet, Eric; Pallet, Nicolas
• Is Part Of: Pharmacogenomics. Volume 18:Number 2(2017)
• Page Start: 165
• Page End: 173
• Publication Date: 2017-01
• Subjects: CYP3A5 -- kidney transplantation -- outcome -- tacrolimus; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2016-0146
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: Meta-analyses and large cohort studies provide confusing results on the association of the CYP3A5 6986A>G allelic variant and adverse outcomes in kidney transplant recipients under tacrolimus-based immunosuppressive regimen. A residual effect of CYP3A5 recipient genotype is unexpected if kidney transplant recipients have similar exposure of tacrolimus.Patients & methods: We have undertaken a population-based, observational study, to investigate all the consecutive patients who received a kidney transplant at the Necker hospital between 2005 and 2015, who were treated with tacrolimus and for whom the CYP3A5 genotype was available.Results & conclusion: We analyzed 577 patients followed for up to 5 years. We found a significant association of CYP3A5 genotypes with tacrolimus daily dose as well as with tacrolimus dose-adjusted concentrations. We however found no association of CYP3A5 genotypes with histology scores on biopsies, measured renal function, biopsy-proven acute rejection episodes and graft survival.